Structured Immunity and Medigene Announce Collaboration Aimed at Improving T Cell Receptor Development

August 21, 2018 8:00 AM

SOUTH BEND, IN and PLANEGG and MARTINSRIED, GERMANY / ACCESSWIRE / August 21, 2018 / Structured Immunity, a biotechnology company specializing in the optimization and validation of T cell receptor (TCR) proteins and Medigene AG, a leading biotechnology company engaged in the development of immunotherapies for the treatment of cancer, today announced a research collaboration where Structured Immunity will provide structural immunology expertise...

Read more

American CryoStem Announces Receipt of Key Business Method Patent for its Cellular Platform

August 21, 2018 6:00 AM

EATONTOWN, NJ / ACCESSWIRE / August 21, 2018 /American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced receipt of Patent No. US 10,014,079 B2 "Business Method for Collecting, Processing, Cryogenic Storage, and Distribution of a Biologic Sample Material"from the U.S....

Read more

Pressure BioSciences, Inc. Reports Second Quarter 2018 Financial Results and Provides Business Update

August 15, 2018 8:26 AM

Major Debt to Equity Conversions, Increasing Revenues, and a Significant Operating Loss Decrease Highlight the 2018 Second Quarter Investor Conference Call Scheduled for Wednesday, August 15, 2018 at 4:30 PM EDT SOUTH EASTON, MA / ACCESSWIRE / August 15, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform...

Read more

Pressure BioSciences, Inc. to Discuss Second Quarter 2018 Financial Results and Provide Business Update

August 10, 2018 9:45 AM

SOUTH EASTON, MA / ACCESSWIRE / August 10, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) (''PBI'' and the ''Company'') today announced that the Company will host a teleconference to discuss its Second Quarter 2018 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website approximately one day after...

Read more

MorphoSys AG Reports Second Quarter 2018 Financial Results

August 1, 2018 4:25 PM

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / August 1, 2018 / The Company has further advanced its pipeline, including proprietary and partnered programs, and established a U.S. footprint to prepare for commercialization in the U.S. Conference call and webcast (in English) to be held on August 2, 2018, at 2:00 pm CEST (1:00 pm BST / 8:00 am EDT) -Ongoing discussions with U.S. FDA regarding path to market for MOR208 as potential therapy for...

Read more

Integrated Biopharma Announces Conversion of $5,350,000 Convertible Debt to Equity

August 1, 2018 4:15 PM

HILLSIDE, NJ / ACCESSWIRE / August 1, 2018 / Integrated BioPharma, Inc. (OTCQB: INBP) (the "Company" or "INBP") announced today the conversion of its Amended and Restated Convertible Secured Promissory Note, in the principal amount of $5,350,000, made by the Company and payable to the order of the CD Financial, LLC (the "Note") into common stock of INBP. CD Financial, LLC exercised its right to convert the entire principal amount of the Note...

Read more

MorphoSys to Host Q2 2018 Conference Call on August 2, 2018

July 25, 2018 8:30 AM

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 25, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYF; NASDAQ: MOR) will publish its first six months' 2018 results on August 1st, 2018 at 10:00 p.m. CEST (4 p.m. EDT; 9 p.m. BST). The Management team of MorphoSys AG will host a conference call and webcast on August 2nd,2018 at 2:00 p.m. CEST to present MorphoSys's Half-Year Report 2018 and provide further details on...

Read more

MorphoSys Announces Appointment of Jennifer Herron as President of MorphoSys US Inc. and Executive Vice President, Global Commercial

July 24, 2018 4:38 PM

PLANEGG/MUNICH, GERMANY and MECHELEN, BELGIUM / ACCESSWIRE / July 24, 2018 / MorphoSys AG (NASDAQ: MOR), (FSE: MOR), (XETRA: MOR) announced today the appointment of Jennifer L. Herron as President of MorphoSys US Inc. and Executive Vice President, Global Commercial, effective July 23, 2018. Ms. Herron was also appointed as member of the Board of Directors of MorphoSys US Inc. In this newly created role, Ms. Herron will lead the build of...

Read more

Pressure BioSciences Developing Potential Breakthrough Processing Method for High Quality, Shelf Stable Milk and Other Dairy Products

July 19, 2018 9:21 AM

Primary Goal is Delivery of Higher Quality, Longer Lasting Liquid Foods and Beverages not Requiring Refrigeration or Chemical Additives SOUTH EASTON, MA / ACCESSWIRE / July 19, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences industry, today announced a major collaboration with the College of...

Read more

MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Pharma Partner

July 19, 2018 8:59 AM

- Exclusive global license agreement with Novartis on MOR106 - MOR106, a monoclonal antibody directed against IL-17C, will be developed further in atopic dermatitis (AtD) and potentially other indications - Up-front payment of EUR 95 million (USD 111 million*) and potential milestone payments of up to approximately EUR 850 million (USD 1 billion*) plus royalties up to low-teens to low-twenties - Novartis to bear all future research, development,...

Read more

Ad hoc: MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Novartis and MorphoSys Increases its Financial Guidance for 2018

July 19, 2018 8:55 AM

PLANEGG/MUNICH, GERMANY and MECHELEN, BELGIUM / ACCESSWIRE / July 19, 2018 / MorphoSys AG (NASDAQ: MOR), (FSE: MOR), (XETRA: MOR) announces today that MorphoSys and Galapagos NV have entered into a worldwide, exclusive agreement with Novartis Pharma AG covering the development and commercialization of their joint program MOR106. MorphoSys furthermore announces that, in consequence of this agreement with Galapagos and Novartis, it increases its...

Read more

Qrons and Dartmouth College Enter into One Year Sponsored Research Agreement

July 18, 2018 9:15 AM

Sponsored Research Agreement Will Allow for Continued Research in Developing Innovative 3D Printable, Bio Compatible Advanced Materials and Stem Cell Delivery Techniques for Qrons' Traumatic Brain Injury Treatment; Qrons Will Also Have the Option to Negotiate Exclusive Licenses MIAMI, FL / ACCESSWIRE / July 18, 2018 / Qrons Inc. (OTC PINK: QRON) ("Qrons " or the "Company"), a preclinical biotechnology company developing advanced cell-based...

Read more

DCprime and Glycotope announce licensing agreement and collaboration

July 18, 2018 2:50 AM

LEIDEN, THE NETHERLANDS, AND BERLIN, GERMANY / ACCESSWIRE / July 18, 2018 / DCprime BV, a clinical stage biotechnology company focused on cell-based cancer vaccines, and Glycotope GmbH, a clinical stage immuno-oncology company built on world-leading glycobiology expertise, announce today that they have entered into a license agreement and research collaboration. Under the agreement, DCprime has obtained the global research and commercialization...

Read more

Oncolix, Inc. Forms Scientific and Clinical Advisory Board and Appoints First Member

July 17, 2018 7:20 AM

HOUSTON, TX / ACCESSWIRE / July 17, 2018 / Oncolix, Inc. (OTCQB: ONCX) (the "Company"), a biotechnology company focused on gynecological cancers, announced that the Company has appointed Robert Niecestro, PhD as its first member of its Regulatory Strategy, Scientific and Clinical Advisory Board. "Dr. Niecestro is a valuable resource to Oncolix because we want to properly navigate Prolanta and new acquisitions through the worldwide regulatory...

Read more

AcuityBio Corporation to Present at the 144th NIBA Investment Conference

July 16, 2018 8:00 AM

NEW YORK CITY, NY / ACCESSWIRE / July 16, 2018 / AcuityBio Corporation (www.acuitybio.com) is a private company, focused on preventing post-surgical lung cancer recurrence via targeted drug-delivery. AcuityBio's first product candidate is "ABC103," their innovative drug-device combination product, which has been granted FDA Orphan Drug designation. AcuityBio announced today that its CEO, Dr. John 'Jay' Schwartz will be describing their ABC103...

Read more

American CryoStem Announces Launch of ATGRAFT(TM) in China

July 12, 2018 6:00 AM

EATONTOWN, NJ / ACCESSWIRE / July 12, 2018 / American CryoStem Corporation (OTC PINK: CRYO), a leading strategic application developer, marketer, and global licensor of patented adipose tissue-based cellular technologies, for the Regenerative and Personalized Medicine industries, today announced the national launch of CRYO's ATGRAFTTM tissue collection, processing and storage technology by Baoxin Asia Pacific Biotechnology (Shenzhen) Co. Ltd....

Read more

MorphoSys Announces its Licensee Janssen has Initiated a Phase 2/3 Program (GALAXI) to Evaluate Tremfya(R) (Guselkumab) in Crohn's Disease

July 10, 2018 4:25 PM

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 10, 2018 / MorphoSys AG (NASDAQ: MOR), (FSE: MOR), (XETRA: MOR) announced today that its licensee Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), has initiated a pivotal phase 2/3 clinical program to evaluate the efficacy and safety of Tremfya(R) (guselkumab) in the treatment of patients with moderately to severely active...

Read more

Oncolix, Inc. Expands Management Team with New Vice President of Corporate Development

July 5, 2018 7:20 AM

HOUSTON, TX / ACCESSWIRE / July 5, 2018 / Oncolix, Inc. (OTCQB: ONCX) (the "Company"), a biotechnology company focused on gynecological cancers, announced that Andrew Scott has joined the Company as its Vice President of Corporate Development. "Andrew is a seasoned veteran that understands the important roles of Investor Relations, banking relationships and raising capital," said Michael T. Redman, president and chief executive officer of...

Read more

Calmare Therapeutics Incorporated Reports Final Tally of Consents by Shareholders of Record

July 2, 2018 5:35 PM

FAIRFIELD, CT / ACCESSWIRE / July 2, 2018 / Calmare Therapeutics Incorporated, (OTC PINK: CTTC) ("CTI"), the pain mitigation company ("Calmare"), today reported the final tabulation of consents by shareholders of record as tallied and prepared by IVS Associates Inc., a professional services organization specializing in independent tabulation and certification of voting results. As per the final tally, none of the proposals carried. Out of...

Read more

Vitro Bio-Pharma 2nd Quarter Ended April 30th 2018 Financial Results of Operations

June 26, 2018 11:00 AM

GOLDEN, CO / ACCESSWIRE / June 26, 2018 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro BioPharma, announced its 2nd quarter ended April 30th 2018 financial results of operations. Vitro Diagnostics Inc. (''Vitro'') is pleased to announce a record 2nd quarter in Stem Cell Revenues. Vitro recorded 2nd quarter revenues of $125,886 vs $56,633 an increase of 222% over the same comparative quarter last year. In addition, Stem Cell therapies...

Read more